These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://phoeberxra664591.anchor-blog.com/19518241/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide